Literature DB >> 23241883

Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes.

Christopher R Lucas1, Hector M Cordero-Nieves, Robert S Erbe, Jaclyn W McAlees, Sumeena Bhatia, Richard J Hodes, Kerry S Campbell, Virginia M Sanders.   

Abstract

CD86 engagement on a CD40L/IL-4-primed murine B cell activates signaling intermediates that promote NF-κB activation to increase Oct-2 and mature IgG1 mRNA and protein expression, as well as the rate of IgG1 transcription, without affecting class switch recombination. One of the most proximal signaling intermediates identified is phospholipase Cγ2, a protein reported to bind tyrosine residues, which are absent in the cytoplasmic domain of CD86. Using a proteomics-based identification approach, we show that the tyrosine-containing transmembrane adaptor proteins prohibitin (Phb)1 and Phb2 bind to CD86. The basal expression of Phb1/2 and association with CD86 was low in resting B cells, whereas the level of expression and association increased primarily after priming with CD40. The CD86-induced increase in Oct-2 and IgG1 was less when either Phb1/2 expression was reduced by short hairpin RNA or the cytoplasmic domain of CD86 was truncated or mutated at serine/threonine protein kinase C phosphorylation sites, which did not affect Phb1/2 binding to CD86. Using this approach, we also show that Phb1/2 and the CD86 cytoplasmic domain are required for the CD86-induced phosphorylation of IκBα, which we previously reported leads to NF-κB p50/p65 activation, whereas only Phb1/2 was required for the CD86-induced phosphorylation of phospholipase Cγ2 and protein kinase Cα/β(II), which we have previously reported leads to NF-κB (p65) phosphorylation and subsequent nuclear translocation. Taken together, these findings suggest that Phb1/2 and the CD86 cytoplasmic domain cooperate to mediate CD86 signaling in a B cell through differential phosphorylation of distal signaling intermediates required to increase IgG1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241883      PMCID: PMC3538926          DOI: 10.4049/jimmunol.1201646

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Involvement of CRAF1, a relative of TRAF, in CD40 signaling.

Authors:  G Cheng; A M Cleary; Z S Ye; D I Hong; S Lederman; D Baltimore
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

2.  TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40.

Authors:  M Rothe; V Sarma; V M Dixit; D V Goeddel
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

Review 3.  CD28/B7 system of T cell costimulation.

Authors:  D J Lenschow; T L Walunas; J A Bluestone
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 4.  Prohibitin: a potential target for new therapeutics.

Authors:  Suresh Mishra; Leigh C Murphy; B L Gregoire Nyomba; Liam J Murphy
Journal:  Trends Mol Med       Date:  2005-04       Impact factor: 11.951

Review 5.  Signal transduction from the B cell antigen-receptor.

Authors:  K S Campbell
Journal:  Curr Opin Immunol       Date:  1999-06       Impact factor: 7.486

6.  Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region.

Authors:  T Ishida; S i Mizushima; S Azuma; N Kobayashi; T Tojo; K Suzuki; S Aizawa; T Watanabe; G Mosialos; E Kieff; T Yamamoto; J Inoue
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

7.  BLNK required for coupling Syk to PLC gamma 2 and Rac1-JNK in B cells.

Authors:  M Ishiai; M Kurosaki; R Pappu; K Okawa; I Ronko; C Fu; M Shibata; A Iwamatsu; A C Chan; T Kurosaki
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

8.  Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40.

Authors:  N Tsukamoto; N Kobayashi; S Azuma; T Yamamoto; J Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling.

Authors:  T K Ishida; T Tojo; T Aoki; N Kobayashi; T Ohishi; T Watanabe; T Yamamoto; J Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

Authors:  G J Freeman; V A Boussiotis; A Anumanthan; G M Bernstein; X Y Ke; P D Rennert; G S Gray; J G Gribben; L M Nadler
Journal:  Immunity       Date:  1995-05       Impact factor: 31.745

View more
  13 in total

Review 1.  Prohibitin: A hypothetical target for sex-based new therapeutics for metabolic and immune diseases.

Authors:  Suresh Mishra; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-04

2.  Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells.

Authors:  Chandana Koorella; Jayakumar R Nair; Megan E Murray; Louise M Carlson; Stephanie K Watkins; Kelvin P Lee
Journal:  J Biol Chem       Date:  2014-01-10       Impact factor: 5.157

Review 3.  Neuroendocrine regulation of inflammation.

Authors:  Caroline J Padro; Virginia M Sanders
Journal:  Semin Immunol       Date:  2014-01-31       Impact factor: 11.130

Review 4.  Prohibitin - At the crossroads of obesity-linked diabetes and cancer.

Authors:  Suresh Mishra; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-11

5.  Adrenergic regulation of IgE involves modulation of CD23 and ADAM10 expression on exosomes.

Authors:  Caroline J Padro; Todd M Shawler; Matthew G Gormley; Virginia M Sanders
Journal:  J Immunol       Date:  2013-10-18       Impact factor: 5.422

6.  The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.

Authors:  Ana M Cosialls; Helena Pomares; Daniel Iglesias-Serret; José Saura-Esteller; Sonia Núñez-Vázquez; Diana M González-Gironès; Esmeralda de la Banda; Sara Preciado; Fernando Albericio; Rodolfo Lavilla; Gabriel Pons; Eva M González-Barca; Joan Gil
Journal:  Haematologica       Date:  2017-06-15       Impact factor: 9.941

Review 7.  Prohibitin: a prime candidate for a pleiotropic effector that mediates sex differences in obesity, insulin resistance, and metabolic dysregulation.

Authors:  Yang Xin Zi Xu; Geetika Bassi; Suresh Mishra
Journal:  Biol Sex Differ       Date:  2019-05-22       Impact factor: 5.027

8.  Electromagnetic fields alter the motility of metastatic breast cancer cells.

Authors:  Ayush Arpit Garg; Travis H Jones; Sarah M Moss; Sanjay Mishra; Kirti Kaul; Dinesh K Ahirwar; Jessica Ferree; Prabhat Kumar; Deepa Subramaniam; Ramesh K Ganju; Vish V Subramaniam; Jonathan W Song
Journal:  Commun Biol       Date:  2019-08-08

Review 9.  Prohibitin: a potential therapeutic target in tyrosine kinase signaling.

Authors:  Sudharsana Rao Ande; Yang Xin Zi Xu; Suresh Mishra
Journal:  Signal Transduct Target Ther       Date:  2017-12-15

10.  The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies.

Authors:  Jeremy A Ross; Elisa Robles-Escajeda; Derrick M Oaxaca; Diana L Padilla; Robert A Kirken
Journal:  Oncotarget       Date:  2017-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.